Momelotinib (MMB) + Trametinib
Phase 1Terminated 0 views this week 0 watching💤 Quiet
Interest: 21/100
21
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Relapsed Metastatic KRAS-Mutated Non-Small Cell Lung Cancer
Conditions
Relapsed Metastatic KRAS-Mutated Non-Small Cell Lung Cancer
Trial Timeline
Mar 11, 2015 → Feb 27, 2017
NCT ID
NCT02258607About Momelotinib (MMB) + Trametinib
Momelotinib (MMB) + Trametinib is a phase 1 stage product being developed by GSK plc for Relapsed Metastatic KRAS-Mutated Non-Small Cell Lung Cancer. The current trial status is terminated. This product is registered under clinical trial identifier NCT02258607. Target conditions include Relapsed Metastatic KRAS-Mutated Non-Small Cell Lung Cancer.
What happened to similar drugs?
2 of 20 similar drugs in Relapsed Metastatic KRAS-Mutated Non-Small Cell Lung Cancer were approved
Approved (2) Terminated (2) Active (16)
🔄SHR2554; Chidamide analog tablets + SHR2554 analog tablets; ChidamideJiangsu Hengrui MedicinePhase 3
Hype Score Breakdown
Clinical
6
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02258607 | Phase 1 | Terminated |
Competing Products
20 competing products in Relapsed Metastatic KRAS-Mutated Non-Small Cell Lung Cancer